stockrow
Monday 9 November 2026
Export ORMP’s income statement to Excel — free account
Oramed Pharmaceuticals Inc.
ORMPOramed Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 49.3% from fiscal 2023.
- Revenue
- +193.3%
- EPS
- +493.8%
- Free cash flow
- +94.3%
Quarter to June 2026, against a year earlier
3.86
0.03
−0.77%
Follow ORMP
Alert me
| Aug '18 | Aug '19 | Aug '20 | Aug '21 | Dec '21 | Aug '22 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 5 | 4 | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.50 | — | 1.88 |
P/S ratio |
30.08 | 20.79 | 26.44 | 238.42 | 194.84 | 123.22 | 178.90 | 36.54 | — | 29.35 |
Altman Z-Score |
0.45 | (1.34) | 0.91 | 28.25 | 28.10 | 17.17 | 25.74 | 0.33 | — | 1.91 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 107.97 | 0.00 | 0.00 | 0.00 | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
(1.01) | (3.83) | (0.31) | 11.00 | 18.01 | 14.68 | 16.30 | 3.41 | — | 7.80 |
P/Operating CF |
(5.03) | (4.34) | (5.76) | (102.70) | 190.84 | (39.11) | (59.98) | (69.66) | — | (253.22) |
P/B ratio |
2.37 | 2.90 | 2.18 | 5.53 | 3.18 | 2.17 | 3.20 | 0.61 | — | 0.59 |
Dividend Safety Score |
— | — | — | — | — | — | — | — | — | 45 |
Price to Tangible BV |
2.37 | 2.90 | 2.18 | 5.53 | 3.18 | 2.17 | 3.20 | 0.61 | — | 0.59 |
EV/Sales |
17.64 | 8.85 | 11.72 | 203.61 | 141.06 | 73.53 | 121.29 | (23.41) | — | (1.96) |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.06 | — | 0.53 |
EV/Operating CF |
(1.58) | (0.89) | (1.25) | (37.85) | 82.77 | (25.27) | (11.74) | 6.15 | — | 0.86 |
EV/FCF |
(1.58) | (0.89) | (1.25) | (37.60) | 78.17 | (26.18) | (11.55) | 6.00 | — | 0.86 |
Quick Ratio |
6.69 | 6.08 | 8.80 | 14.09 | 19.85 | 27.10 | 27.10 | 3.05 | 24.97 | 6.60 |
Current Ratio |
6.82 | 6.28 | 8.93 | 14.27 | 20.08 | 27.34 | 27.34 | 3.06 | 25.19 | 6.98 |
Net Debt/EBITDA |
2.25 | 2.21 | 3.40 | 3.90 | 11.89 | 3.84 | 3.84 | 10.41 | 11.28 | 8.41 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.06 | 0.07 | 0.07 | 0.03 | 0.01 | 0.02 | 0.02 | 0.01 | 0.00 | 0.01 |
Operating CF/Net income |
1.15 | 0.90 | 1.08 | 0.95 | 0.95 | 0.79 | 0.76 | (1.86) | 0.44 | (0.14) |
Capex/Depreciation |
(0.83) | (1.87) | (11.71) | (4.87) | (0.50) | 0.00 | (8.14) | (1.30) | (0.09) | (0.07) |
Interest Coverage |
(131.33) | (30.17) | (26.48) | (3,027.87) | (141.68) | (22.72) | (49.51) | (7.74) | (14.98) | — |
| (50.55%) | (56.85%) | (44.04%) | (29.77%) | (8.24%) | (22.96%) | (24.14%) | 3.52% | (12.37%) | 36.65% | |
| (29.56%) | (34.99%) | (29.03%) | (25.76%) | (7.63%) | (21.54%) | (22.62%) | 2.89% | (10.14%) | 32.76% | |
ROIC |
(1,302.68%) | 0.00% | 0.00% | (67.66%) | (37.89%) | 0.00% | 0.00% | (1,164.97%) | (233.78%) | (12.77%) |
Return on Tangible Assets |
(48.02%) | (51.19%) | (31.91%) | (24.97%) | (8.28%) | (23.87%) | (24.03%) | 5.01% | (13.79%) | 55.10% |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 |
Research and Development Expense of Revenue |
489.14% | 500.26% | 377.68% | 776.51% | 999.67% | 1,020.38% | 1,022.53% | 669.48% | 0.00% | 319.05% |
Selling, General and Administrative Expense of Revenue |
166.72% | 137.70% | 156.16% | 219.64% | 463.83% | 579.43% | 579.43% | 607.31% | 0.00% | 436.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
63.17% | 29.89% | 17.16% | 99.70% | 196.46% | 0.00% | 425.79% | 314.33% | 0.00% | 299.60% |
Graham Net Nets |
0.20 | 0.32 | 0.40 | 0.13 | 0.26 | 0.38 | 0.30 | 1.06 | — | 0.87 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.57 | — | 12.85 |
Earnings Yield |
(17.37%) | (17.45%) | (16.36%) | (3.53%) | (6.03%) | (11.46%) | (7.58%) | 5.71% | — | 53.33% |
Free Cash Flow Yield |
(37.21%) | (47.65%) | (35.59%) | (2.27%) | 0.93% | (2.28%) | (5.87%) | (10.68%) | — | (7.76%) |
Revenue per Share |
0.16 | 0.15 | 0.13 | 0.09 | 0.02 | 0.07 | 0.07 | 0.03 | 0.00 | 0.05 |
Operating CF per Share |
(0.98) | (0.74) | (0.61) | (0.74) | (0.30) | (0.74) | (0.72) | (0.26) | (0.21) | (0.22) |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | (0.01) | (0.01) | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.99) | (0.74) | (0.61) | (0.76) | (0.30) | (0.74) | (0.73) | (0.26) | (0.21) | (0.22) |
Cash per Share |
2.05 | 1.85 | 1.94 | 3.31 | 3.94 | 3.99 | 3.99 | 4.02 | 3.47 | 3.04 |
Shareholders Equity per Share |
2.09 | 1.11 | 1.60 | 4.09 | 4.49 | 3.89 | 3.88 | 4.04 | 3.56 | 4.82 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.09 | 1.11 | 1.60 | 4.09 | 4.49 | 3.89 | 3.88 | 4.04 | 3.56 | 4.82 |
Free Cash Flow |
(14.66) | (12.95) | (12.52) | (21.56) | (11.13) | (28.70) | (28.39) | (10.55) | (8.43) | (9.15) |
Working Capital |
26.48 | 28.02 | 35.98 | 88.66 | 140.57 | 151.36 | 151.36 | 109.37 | 137.54 | 114.19 |
Capital Expenditures |
0.00 | (0.01) | (0.08) | (0.37) | (0.01) | (0.50) | (0.47) | (0.25) | (0.02) | (0.01) |
Net Current Asset Value |
14.75 | 18.05 | 28.76 | 83.86 | 136.73 | 146.62 | 146.62 | 104.93 | 133.29 | 102.15 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.01 | — | 0.52 |
Capex to Sales |
0.00 | 0.01 | 0.03 | 0.14 | 0.01 | 0.00 | 0.17 | 0.19 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.35 | 0.33 | 0.07 | 0.19 | 0.05 | 0.03 | 0.07 | 0.22 | 0.28 | 0.21 |
Cash ROIC |
(23.81%) | (25.07%) | (17.21%) | (10.23%) | (3.56%) | (9.33%) | (9.25%) | (3.25%) | (2.93%) | (2.81%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 |
Accounts Payable Turnover |
(0.04) | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.32 |
Inventory Turnover |
0.00 | 0.00 | — | — | — | — | — | — | — | 0.00 |
Average Days of Payables |
(8,929.77) | 10,564.72 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,258.86 |
Days of Inventory on Hand |
0.00 | 0.00 | — | — | — | — | — | — | — | 0.00 |
Average Payables |
2.41 | 2.35 | 2.20 | 2.82 | 4.19 | 3.36 | 3.17 | 3.05 | 3.70 | 6.16 |
Average Assets |
43.05 | 41.03 | 39.65 | 86.32 | 152.91 | 169.73 | 161.64 | 191.10 | 187.91 | 193.07 |
Average Common Equity |
25.18 | 25.25 | 26.14 | 74.70 | 141.56 | 159.21 | 151.48 | 157.02 | 154.12 | 172.55 |
Columns are period end dates · fundamentals updated 2 Nov 2026